In final pivot from cancer to rare disease, Agios offloads its share of Tibsovo royalties for $131M
Almost two years after Agios sold its oncology unit to French pharma Servier in a $1.8 billion deal, Agios is letting go of its last link to one of its old medicines.
Agios announced Thursday that it went ahead and sold its rights to 5% royalties on US net sales of Servier’s Tibsovo (ivosidenib) to Sagard Healthcare Partners for a one-time payment of $131.8 million. Agios had sold off its oncology business, including Tibsovo, to the French pharma back in 2020, closing the sale in early 2021.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.